Elihu Estey

List of Publications by Citations

163 papers	15,302 citations	44 h-index	123 g-index
176 ext. papers	18,137 ext. citations	5 avg, IF	6.56 L-index

#	Paper	IF	Citations
163	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, **2017**, 129, 424-447	2.2	2764
162	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*, **2010**, 115, 453-74	2.2	2483
161	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2003**, 21, 4642-9	2.2	2107
160	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer*, **2006**, 106, 1090-8	6.4	478
159	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncology, The*, **2014**, 15, 986-96	21.7	410
158	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. *Cancer*, **2005**, 104, 1442-52	6.4	364
157	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. *Blood*, **2006**, 107, 3469-73	2.2	317
156	Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. *Journal of Clinical Oncology*, **2009**, 27, 504-10	2.2	306
155	Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. *Journal of Clinical Oncology*, **2014**, 32, 3249-56	2.2	273
154	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. *Journal of Clinical Oncology*, **2016**, 34, 329-36	2.2	270
153	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 1190-7	2.2	270
152	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood*, **2013**, 122, 1813-21	2.2	264
151	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *Journal of Clinical Oncology*, **2011**, 29, 4417-23	2.2	230
150	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood*, **2019**, 133, 1630-1643	2.2	219
149	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. *Blood*, **2012**, 119, 6198-208	2.2	217
148	Acute myeloid leukemia: 2013 update on risk-stratification and management. *American Journal of Hematology*, **2013**, 88, 318-27	7.1	214
147	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Blood*, **2007**, 109, 1395-400	2.2	209

146	Acute myeloid leukemia: 2019 update on risk-stratification and management. *American Journal of Hematology*, **2018**, 93, 1267-1291	7.1	171
145	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *Journal of Clinical Oncology*, **2015**, 33, 1258-64	2.2	163
144	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. *Blood*, **2009**, 113, 28-36	2.2	162
143	Acute myeloid leukaemia. *Nature Reviews Disease Primers*, **2016**, 2, 16010	51.1	159
142	Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. *Blood*, **2002**, 99, 4222-4	2.2	156
141	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. *Journal of Clinical Oncology*, **2010**, 28, 1766-71	2.2	145
140	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2018** , 19, 889-903	21.7	145
139	Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab. *Blood*, **2017**, 129, 1275-1283	2.2	144
138	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. *Blood*, **2002**, 99, 4343-9	2.2	130
137	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2012**, 87, 89-99	7.1	118
136	The past and future of CD33 as therapeutic target in acute myeloid leukemia. *Blood Reviews*, **2014**, 28, 143-53	11.1	107
135	Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. *Cancer*, **2003**, 97, 2218-24	6.4	106
134	Acute myeloid leukemia: 2014 update on risk-stratification and management. *American Journal of Hematology*, **2014**, 89, 1063-81	7.1	104
133	New designs for phase 2 clinical trials. *Blood*, **2003**, 102, 442-8	2.2	96
132	Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. *Journal of Clinical Oncology*, **2015**, 33, 1157-64	2.2	86
131	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. *Blood*, **2011**, 118, 1490-4	2.2	86
130	Gemtuzumab ozogamicin: time to resurrect?. *Journal of Clinical Oncology*, **2012**, 30, 3921-3	2.2	84
129	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. *Blood*, **2000**, 95, 72-77	2.2	82

128	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. *Blood*, **2012**, 120, 673-673	2.2	81
127	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. *JAMA Oncology*, **2017**, 3, 1675-1682	13.4	78
126	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. *Haematologica*, **2015**, 100, 927-34	6.6	74
125	Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. *Journal of Clinical Oncology*, **2003**, 21, 1722-7	2.2	73
124	Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work. *Blood*, **1997**, 90, 4719-4724	2.2	70
123	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood*, **2010**, 116, 2420-8	2.2	62
122	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. *Blood*, **2015**, 125, 2461-6	2.2	59
121	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2012**, 120, 48-48	2.2	54
120	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. *Frontiers in Bioscience - Landmark*, **2013**, 18, 1311-34	2.8	46
119	Acute myeloid leukemia: 2016 Update on risk-stratification and management. *American Journal of Hematology*, **2016**, 91, 824-46	7.1	43
118	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. *Blood Reviews*, **2017**, 31, 185-192	11.1	42
117	Using short-term response information to facilitate adaptive randomization for survival clinical trials. *Statistics in Medicine*, **2009**, 28, 1680-9	2.3	41
116	Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. *Journal of Clinical Oncology*, **2019**, 37, 2632-2642	2.2	40
115	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 549-55	4.7	38
114	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. *Journal of Clinical Oncology*, **2013**, 31, 3883-8	2.2	35
113	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. *Haematologica*, **2008**, 93, 1263-5	6.6	35
112	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 4050-4050	2.2	34
111	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. *JAMA Oncology*, **2015**, 1, 1120-7	13.4	33

110	Time to repeal and replace response criteria for acute myeloid leukemia?. *Blood Reviews*, **2018**, 32, 416-425	12.1	33
109	Accounting for patient heterogeneity in phase II clinical trials. *Statistics in Medicine*, **2008**, 27, 2802-15	2.3	32
108	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. *Leukemia*, **2020**, 34, 671-681	10.7	32
107	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. *Hematology American Society of Hematology Education Program*, **2014**, 2014, 21-33	3.1	29
106	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 571-7	0.6	27
105	AML in older patients: are we making progress?. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 529-36	4.2	26
104	Acute myeloid leukemia: 2021 update on risk-stratification and management. *American Journal of Hematology*, **2020**, 95, 1368-1398	7.1	25
103	Relapse and death during first remission in acute myeloid leukemia. *Haematologica*, **2008**, 93, 633-4	6.6	24
102	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. *Leukemia*, **2018**, 32, 2352-2362	10.7	21
101	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1615-1620	4.7	20
100	Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 546-51	4.7	19
99	Treatment of AML: resurrection for gemtuzumab ozogamicin?. *Lancet, The*, **2012**, 379, 1468-9	40	19
98	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. *Blood*, **2013**, 122, 61-61	2.2	19
97	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 421-432	7.1	18
96	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. *Haematologica*, **2018**, 103, e106-e109	6.6	18
95	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. *Blood*, **2016**, 128, 216-216	2.2	16
94	Why Is Progress in Acute Myeloid Leukemia So Slow?. *Seminars in Hematology*, **2015**, 52, 243-8	4	15
93	Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. *Current Medical Research and Opinion*, **2018**, 34, 2031-2039	2.5	14

92	New drugs in acute myeloid leukemia. *Seminars in Oncology*, **2008**, 35, 439-48	5.5	14
91	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. *Blood*, **2021**,	2.2	14
90	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. *Blood Reviews*, **2020**, 44, 100679	11.1	12
89	Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. *Thrombosis Research*, **2016**, 141, 104-5	8.2	12
88	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). *Journal of Drug Assessment*, **2018**, 7, 51-53	1.5	11
87	High cytogenetic or molecular genetic risk acute myeloid leukemia. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 474-80	3.1	11
86	Reply to D. Przepiorka et al. *Journal of Clinical Oncology*, **2015**, 33, 3676-7	2.2	10
85	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood Advances*, **2020**, 4, 611-616	7.8	10
84	Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. *Leukemia Research*, **2020**, 89, 106298	2.7	9
83	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. *Haematologica*, **2015**, 100, e409-11	6.6	9
82	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. *JAMA Oncology*, **2019**, 5, 1062-1064	13.4	8
81	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. *Haematologica*, **2015**, 100, e97-8	6.6	8
80	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. *Blood*, **2013**, 122, 356-356	2.2	8
79	Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 324-328	4.2	7
78	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. *Leukemia and Lymphoma*, **2021**, 62, 1226-1233	1.9	7
77	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. *Blood Advances*, **2020**, 4, 3239-3245	7.8	6
76	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. *Leukemia*, **2019**, 33, 554-558	10.7	6
75	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. *Leukemia*, **2019**, 33, 371-378	10.7	6

74	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. *Leukemia*, **2020**, 34, 635-639	10.7	6
73	Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. *Cancer*, **2019**, 125, 3121-3130	6.4	5
72	A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 395-400.e1	2	5
71	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. *Leukemia Research*, **2014**, 38, 258-62	2.7	5
70	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. *Blood*, **2013**, 122, 3924-3924	2.2	5
69	Emerging treatments in acute myeloid leukemia: current standards and unmet challenges. *Clinical Advances in Hematology and Oncology*, **2017**, 15, 632-642	0.6	5
68	Primacy of resistance rather than toxicity in determining outcome of therapy for AML. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14 Suppl, S56-8	2	4
67	Management of persistent AML at day 14. *Best Practice and Research in Clinical Haematology*, **2014**, 27, 235-40	4.2	4
66	Intensity of conditioning for allogeneic haemopoetic cell transplantation. *Lancet Oncology, The*, **2012**, 13, 966-8	21.7	4
65	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. *Blood*, **2008**, 112, 3253-3253	2.2	4
64	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. *Blood*, **2013**, 122, 3925-3925	2.2	4
63	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 7021-7021	2.2	4
62	Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?. *Journal of Clinical Oncology*, **2019**, 37, 7031-7031	2.2	4
61	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. *Leukemia and Lymphoma*, **2019**, 60, 1023-1029	1.9	4
60	New treatments for acute myeloid leukemia: how much has changed?. *Leukemia*, **2021**, 35, 45-46	10.7	4
59	Response in acute myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 113-7	0.6	4
58	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. *Haematologica*, **2015**, 100, e254-6	6.6	3
57	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. *Leukemia and Lymphoma*, **2015**, 56, 782-4	1.9	3

56	The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. *Blood*, **2013**, 122, 293-4	2.2	3
55	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. *Blood*, **2019**, 134, 1364-1364	2.2	3
54	The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. *British Journal of Haematology*, **2021**,	4.5	3
53	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. *Haematologica*, **2021**, 106, 2114-2120	6.6	3
52	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). *Leukemia Research Reports*, **2013**, 2, 26-8	0.6	2
51	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. *Blood*, **2018**, 132, 1513-1513	2.2	2
50	Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. *Blood*, **2019**, 134, 3824-3824	2.2	2
49	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 260-260	2.2	2
48	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. *Blood*, **2013**, 122, 3936-3936	2.2	2
47	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. *Blood*, **2013**, 122, 483-483	2.2	2
46	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. *Blood*, **2016**, 128, 1613-1613	2.2	2
45	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. *Leukemia and Lymphoma*, **2021**, 62, 234-238	1.9	2
44	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function.. *Cell Stem Cell*, **2022**,	18	2
43	What is the optimal induction strategy for older patients?. *Best Practice and Research in Clinical Haematology*, **2011**, 24, 515-22	4.2	1
42	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). *Blood*, **2019**, 134, 4585-4585	2.2	1
41	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. *Blood*, **2019**, 134, 2729-2729	2.2	1
40	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. *Blood*, **2013**, 122, 5002-5002	2.2	1
39	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2569-2569	2.2	1

38	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 1-10	7.3	1
37	A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131).. *Journal of Clinical Oncology*, **2015**, 33, TPS7096-TPS7096	2.2	1
36	An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2602-2602	2.2	1
35	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. *Blood*, **2013**, 122, 64-64	2.2	1
34	Need for routine examination of left ventricular ejection fraction in patients with AML. *Leukemia*, **2020**, 34, 1169-1171	10.7	1
33	Are phase III trials still important for FDA drug approval?. *Leukemia and Lymphoma*, **2021**, 62, 1287-1288	1.9	1
32	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). *Leukemia and Lymphoma*, **2021**, 62, 1532-1535	1.9	1
31	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 2108-2117	4.4	1
30	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. *Leukemia and Lymphoma*, **2016**, 57, 1205-7	1.9	1
29	'Looking beyond survival to define therapeutic value in acute myeloid leukemia'. *Leukemia and Lymphoma*, **2019**, 60, 1107-1109	1.9	1
28	Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 205-206	4.7	1
27	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 12-13	2.2	0
26	Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. *Leukemia and Lymphoma*, **2021**, 1-10	1.9	0
25	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation.. *American Journal of Hematology*, **2022**,	7.1	0
24	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e633-e635	2	
23	Are immunoconjugates approaching "standard of care" in AML?. *Best Practice and Research in Clinical Haematology*, **2013**, 26, 261-8	4.2	
22	The times they are a-changin'. *Blood*, **2011**, 117, 1774-5	2.2	
21	Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 9-10	2.2	

20	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 12-13	2.2
19	More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels. *Leukemia and Lymphoma*, **2021**, 1-4	1.9
18	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. *Blood*, **2021**, 138, 502-502	2.2
17	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. *Blood*, **2021**, 138, 4040-4040	2.2
16	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. *Blood*, **2018**, 132, 3978-3978	2.2
15	Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia. *Blood*, **2019**, 134, 4674-4674	2.2
14	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. *Blood*, **2019**, 134, 291-291	2.2
13	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. *Blood*, **2015**, 126, 5635-5635	2.2
12	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. *Blood*, **2015**, 126, 3776-3776	2.2
11	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 1339-1339	2.2
10	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. *Blood*, **2015**, 126, 688-688	2.2
9	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. *Blood*, **2016**, 128, 2792-2792	2.2
8	New Designs for Clinical Trials: Acute Myeloid Leukemia as an Example419-428	
7	Acute Myeloid Leukemia (AML) **2012**, 1-36	
6	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified, in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. *Blood* **2012**, 120, 540-540	2.2
5	Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study. *Blood*, **2012**, 120, 4343-4343	2.2
4	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. *Blood*, **2013**, 122, 2932-2932	2.2
3	Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1305-1305	2.2

2	Truth or consequences: under-reporting of post-accrual changes in clinical trial design. *Leukemia and Lymphoma*, **2020**, 61, 2034-2035	1.9
1	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.. *Leukemia Research*, **2022**, 115, 106822	2.7